Cosby A Stone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3299798/publications.pdf

Version: 2024-02-01

166 papers 8,649 citations

43 h-index 86 g-index

170 all docs

170 docs citations

170 times ranked

10215 citing authors

#	Article	IF	CITATIONS
1	Garcinia cambogia, Either Alone or in Combination With Green Tea, Causes Moderate to Severe Liver Injury. Clinical Gastroenterology and Hepatology, 2022, 20, e1416-e1425.	4.4	13
2	Understanding Penicillin Allergy, Cross-reactivity, and Antibiotic Selection in the Preoperative Setting. Journal of the American Academy of Orthopaedic Surgeons, The, 2022, 30, e1-e5.	2.5	6
3	Immediate and Delayed Hypersensitivity Reactions to Beta-Lactam Antibiotics. Clinical Reviews in Allergy and Immunology, 2022, 62, 449-462.	6.5	9
4	Janssen COVID-19 vaccine tolerated in 10 patients with confirmed polyethylene glycol allergy. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 859-862.	3.8	11
5	Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension. Nature Communications, 2022, 13, 46.	12.8	19
6	Low-risk penicillin allergy delabeling through a direct oral challenge in immunocompromised and/or multiple drug allergy labeled patients in a critical care setting. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1660-1663.e2.	3.8	13
7	Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines. Nature Nanotechnology, 2022, 17, 337-346.	31.5	74
8	Abacavir inhibits but does not cause self-reactivity to HLA-B*57:01-restricted EBV specific T cell receptors. Communications Biology, 2022, 5, 133.	4.4	3
9	Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1155-1167.e5.	3.8	52
10	Single-cell immunopathology of systemic contact allergy associated with corticosteroids. Journal of Dermatological Science, 2022, 105, 137-140.	1.9	1
11	HLA-B*07:02 and HLA-C*07:02 are associated with trimethoprim-sulfamethoxazole respiratory failure. Pharmacogenomics Journal, 2022, 22, 124-129.	2.0	5
12	Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models. Immunology and Allergy Clinics of North America, 2022, 42, 285-305.	1.9	4
13	Anaphylaxis to Excipients in Current Clinical Practice. Immunology and Allergy Clinics of North America, 2022, 42, 239-267.	1.9	4
14	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysisâ€"Coordinating Research Priorities to Move the Field Forward. JAMA Dermatology, 2022, 158, 607.	4.1	8
15	<i>ABO</i> O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia. Blood, 2022, 140, 274-284.	1.4	9
16	Drug Hypersensitivity: A Glass Half Full. Immunology and Allergy Clinics of North America, 2022, 42, xiii-xiv.	1.9	0
17	Recognizing Drug Hypersensitivity in Pigmented Skin. Immunology and Allergy Clinics of North America, 2022, 42, 219-238.	1.9	6
18	COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA. Lancet Infectious Diseases, The, 2022, , .	9.1	2

#	Article	IF	Citations
19	Oncologist counseling practice and COVIDâ€19 vaccination outcomes for patients with history of PEGâ€asparaginase hypersensitivity. Pediatric Blood and Cancer, 2022, , e29686.	1.5	2
20	Addressing betaâ€lactam allergy: A time for action. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1091-1093.	5.7	3
21	What have we learned about the allergenicity and adverse reactions associated with the severe acute respiratory syndrome coronavirus 2 vaccines: One year later. Annals of Allergy, Asthma and Immunology, 2022, 129, 40-51.	1.0	14
22	Rapid progress in our understanding of COVID-19 vaccine allergy: AÂcause for optimism, not hesitancy. Journal of Allergy and Clinical Immunology, 2022, 150, 12-16.	2.9	11
23	Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines. JAMA Internal Medicine, 2022, 182, 376.	5.1	66
24	Practical Implementation of Genetics: New Concepts in Immunogenomics to Predict, Prevent, and Diagnose Drug Hypersensitivity. Journal of Allergy and Clinical Immunology: in Practice, 2022, , .	3.8	3
25	Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia. Blood Advances, 2022, 6, 4137-4146.	5.2	7
26	Adverse Events and Safety of SARS-CoV-2 Vaccines: What's New and What's Next. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 2254-2266.	3.8	4
27	Standards for practical intravenous rapid drug desensitization & Description and Standards for practical intravenous rapid drug desensitization & Description & Descriptio	3.5	18
28	Feasibility of a Centralized, Pharmacy-Led Penicillin Allergy Delabeling Program. Hospital Pediatrics, 2022, 12, e230-e237.	1.3	7
29	The Penicillin Allergy Delabeling Program: A Multicenter Whole-of-Hospital Health Services Intervention and Comparative Effectiveness Study. Clinical Infectious Diseases, 2021, 73, 487-496.	5.8	74
30	Cross-reactivity between vancomycin, teicoplanin, and telavancin in patientsÂwith HLA-Aâ^—32:01–positive vancomycin-induced DRESS sharing an HLA class II haplotype. Journal of Allergy and Clinical Immunology, 2021, 147, 403-405.	2.9	26
31	Dose, Timing, and Spectrum of Prenatal Antibiotic Exposure and Risk of Childhood Asthma. Clinical Infectious Diseases, 2021, 72, 455-462.	5.8	16
32	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C9</i> and <i>HLAâ€B</i> Genotypes and Phenytoin Dosing: 2020 Update. Clinical Pharmacology and Therapeutics, 2021, 109, 302-309.	4.7	102
33	Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS). Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 819-829.e2.	3.8	60
34	Anti-PEG IgE in anaphylaxis associated with polyethylene glycol. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1731-1733.e3.	3.8	100
35	Biological treatments in allergy: prescribing patterns and management of hypersensitivity reactions. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1396-1399.e2.	3.8	3
36	Testing Strategies and Predictors for Evaluating Immediate and Delayed Reactions to Cephalosporins. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 435-444.e13.	3.8	20

#	Article	IF	Citations
37	Criteria for intradermal skin testing and oral challenge in patients labeled as fluoroquinolone allergic. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1024-1028.e3.	3.8	8
38	Beta-lactam-induced immediate hypersensitivity reactions: AÂgenome-wide association study of a deeply phenotyped cohort. Journal of Allergy and Clinical Immunology, 2021, 147, 1830-1837.e15.	2.9	26
39	HLAâ€B*35:01 and Green Tea–Induced Liver Injury. Hepatology, 2021, 73, 2484-2493.	7.3	53
40	Maintaining Safety with SARS-CoV-2 Vaccines. New England Journal of Medicine, 2021, 384, 643-649.	27.0	330
41	Safety, Efficacy, and Effectiveness of Delabeling in Patients with Multiple Drug Allergy Labels. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 922-928.	3.8	11
42	Skin Testing for Penicillin Allergy: a Review of the Literature. Current Allergy and Asthma Reports, 2021, 21, 21.	5.3	9
43	DDIWAS: High-throughput electronic health record-based screening of drug-drug interactions. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1421-1430.	4.4	10
44	mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1423-1437.	3.8	351
45	Breaking the Mold: Safely Delabeling Penicillin Allergies in Hospitalized Children. Hospital Pediatrics, 2021, 11, e70-e72.	1.3	4
46	Genomic Risk Factors Driving Immune-Mediated Delayed Drug Hypersensitivity Reactions. Frontiers in Genetics, 2021, 12, 641905.	2.3	11
47	Role of pharmacogenomics in T-cell hypersensitivity drug reactions. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 327-334.	2.3	3
48	The Role of InÂVivo and ExÂVivo Diagnostic Tools in Severe Delayed Immune-Mediated Adverse Antibiotic Drug Reactions. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2010-2015.e4.	3.8	26
49	Visual Genomics Analysis Studio as a Tool to Analyze Multiomic Data. Frontiers in Genetics, 2021, 12, 642012.	2.3	14
50	High-throughput framework forÂgenetic analyses of adverse drug reactions using electronic health records. PLoS Genetics, 2021, 17, e1009593.	3.5	5
51	COVIDâ€19 vaccine anaphylaxis: PEG or not?. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1934-1937.	5.7	22
52	Anaphylaxis to the first dose of mRNA SARS oVâ€2 vaccines: Don't give up on the second dose!. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2916-2920.	5 . 7	59
53	Immunopharmacogenomics: Mechanisms of HLAâ€Associated Drug Reactions. Clinical Pharmacology and Therapeutics, 2021, 110, 607-615.	4.7	29
54	An academic hospital experience screening mRNA COVID-19 vaccine risk using patient allergy history. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3807-3810.	3.8	6

#	Article	IF	CITATIONS
55	Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose. JAMA Internal Medicine, 2021, 181, 1530.	5.1	84
56	DrugWAS: Drugâ€wide Association Studies for COVIDâ€19 Drug Repurposing. Clinical Pharmacology and Therapeutics, 2021, 110, 1537-1546.	4.7	13
57	Reporting of drug reaction with eosinophilia and systemic symptoms from 2002 to 2019 in the US Food and Drug Administration Adverse Event Reporting System. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3208-3211.e1.	3.8	13
58	Allergic Reactions After COVID-19 Vaccinationâ€"Putting Risk Into Perspective. JAMA Network Open, 2021, 4, e2122326.	5.9	5
59	Hidden Dangers: Recognizing Excipients as Potential Causes of Drug and Vaccine Hypersensitivity Reactions. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2968-2982.	3.8	41
60	Considerations for cross-reactivity between vancomycin and other glycopeptides. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3233.	3.8	2
61	mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase. Journal of Allergy and Clinical Immunology: in Practice, 2021, , .	3.8	18
62	Antifungal hypersensitivity reactions and cross-reactivity patterns. Current Opinion in Infectious Diseases, 2021, Publish Ahead of Print, 559-572.	3.1	0
63	Reply to â€~â€~The safety and efficacy of direct oral challenge in trimethoprim-sulfamethoxazole antibiotic allergy― Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3849-3850.	3.8	3
64	CD4+CCR6+ T cells dominate the BCG-induced transcriptional signature. EBioMedicine, 2021, 74, 103746.	6.1	11
65	Dose, Timing, and Type of Infant Antibiotic Use and the Risk of Childhood Asthma. Clinical Infectious Diseases, 2020, 70, 1658-1665.	5.8	37
66	The challenge of de″abeling penicillin allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 273-288.	5.7	136
67	Oral challenge with trimethoprim-sulfamethoxazole in patients with "sulfa―antibiotic allergy. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 757-760.e4.	3.8	37
68	Oral amoxicillin challenges in low-risk children during a pediatric emergency department visit. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1126-1128.e1.	3.8	26
69	Safety of cephalosporins in penicillin class severe delayed hypersensitivity reactions. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1142-1146.e4.	3.8	22
70	Infant Respiratory Syncytial Virus Bronchiolitis and Subsequent Risk of Pneumonia, Otitis Media, and Antibiotic Utilization. Clinical Infectious Diseases, 2020, 71, 211-214.	5.8	8
71	Analysis of Skin-Resident Memory T Cells Following Drug Hypersensitivity Reactions. Journal of Investigative Dermatology, 2020, 140, 1442-1445.e4.	0.7	19
72	Regional and temporal awareness of alpha-gal allergy: An infodemiological analysis using Google Trends. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1725-1727.e1.	3.8	5

#	Article	IF	Citations
73	Tolerance of porcine pancreatic enzymes despite positive skin testing in alpha-gal allergy. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1728-1732.e1.	3.8	14
74	Implications of electronic health record transition on drug allergy labels. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 764-766.	3.8	8
75	Penicillin Allergy Delabeling: A Multidisciplinary Opportunity. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2858-2868.e16.	3.8	55
76	Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, S16-S116.	3.8	107
77	Positioning Drug Allergy Delabeling as a Critical Tool for Precision Medicine, Quality Improvement, and Public Health. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2916-2919.	3.8	5
78	Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2878-2895.e6.	3.8	27
79	A Review of β-Lactam–Associated Neutropenia and Implications for Cross-reactivity. Annals of Pharmacotherapy, 2020, 55, 106002802097564.	1.9	10
80	Readiness for PENicillin allergy testing: Perception of Allergy Label (PEN-PAL) survey. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3180-3182.e4.	3.8	11
81	Penicillin allergy labels drive perioperative prophylactic antibiotic selection in orthopedic procedures. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3634-3636.e1.	3.8	10
82	Patient Characteristics and Concerns about Drug Allergy: A Report from the United States Drug Allergy Registry. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2958-2967.	3.8	19
83	The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. Journal of Allergy and Clinical Immunology, 2020, 146, 518-534.e1.	2.9	180
84	New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals. Human Immunology, 2020, 81, 300-304.	2.4	19
85	Delayed hypersensitivity associated with amoxicillinâ€clavulanate. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2700-2702.	5.7	7
86	Children with reported penicillin allergy. Annals of Allergy, Asthma and Immunology, 2020, 124, 558-565.	1.0	42
87	Pharmacogenomic biomarkers in allergy and immunology practice. Journal of Allergy and Clinical Immunology, 2020, 146, 509-512.	2.9	10
88	Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. British Journal of Clinical Pharmacology, 2020, 86, 1778-1789.	2.4	34
89	SJS/TEN 2019: From science to translation. Journal of Dermatological Science, 2020, 98, 2-12.	1.9	41
90	Development and Validation of a Penicillin Allergy Clinical Decision Rule. JAMA Internal Medicine, 2020, 180, 745.	5.1	135

#	Article	IF	Citations
91	Risk-Stratified Management Offers a Safe Approach to Removing Low-Risk Penicillin Allergy Labels in the Intensive Care Unit. Journal of Allergy and Clinical Immunology, 2020, 145, AB94.	2.9	4
92	Risk-stratified Management to Remove Low-Risk Penicillin Allergy Labels in the ICU. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1572-1575.	5.6	44
93	Anaphylaxis to PEGylated liposomal echocardiogram contrast in a patient with IgE-mediated macrogol allergy. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1416-1419.e3.	3.8	39
94	An Updated Review of the Diagnostic Methods in Delayed Drug Hypersensitivity. Frontiers in Pharmacology, 2020, 11, 573573.	3.5	32
95	Genome-wide Study Identifies Association between HLA-Bâ^—55:01 and Self-Reported Penicillin Allergy. American Journal of Human Genetics, 2020, 107, 612-621.	6.2	34
96	Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions. Annual Review of Pharmacology and Toxicology, 2019, 59, 463-486.	9.4	42
97	Defining Regional Differences in Drugâ€Induced Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis: A Tool to Improve Drug Safety?. Clinical Pharmacology and Therapeutics, 2019, 105, 22-25.	4.7	3
98	Anaphylaxis after vaccination in a pediatric patient: further implicating alpha-gal allergy. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 322-324.e2.	3.8	44
99	A Rapid Allele-Specific Assay for HLA-A*32:01 to Identify Patients at Risk for Vancomycin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms. Journal of Molecular Diagnostics, 2019, 21, 782-789.	2.8	12
100	Reply. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2095-2096.	3.8	0
101	Slow graded reintroduction of oxcarbazepine for delayed maculopapular eruption. Annals of Allergy, Asthma and Immunology, 2019, 123, 411-412.	1.0	3
102	Beta-Lactam and Sulfonamide Allergy Testing Should Be a Standard of Care in Immunocompromised Hosts. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2151-2153.	3.8	22
103	High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia – lessons for immunopathogenesis and prescribing. Leukemia and Lymphoma, 2019, 60, 3455-3460.	1.3	4
104	Immuneâ€mediated adverse reactions to vaccines. British Journal of Clinical Pharmacology, 2019, 85, 2694-2706.	2.4	129
105	Single-cell transcriptomics reveal polyclonal memory T-cell responses in skin with positive abacavir patch test results. Journal of Allergy and Clinical Immunology, 2019, 144, 1413-1416.e7.	2.9	19
106	Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1533-1540.e8.	3.8	257
107	High and variable population prevalence of HLAâ€B*56:02 in indigenous Australians and relation to phenytoinâ€associated drug reaction with eosinophilia and systemic symptoms. British Journal of Clinical Pharmacology, 2019, 85, 2163-2169.	2.4	19
108	Widespread Tau-Specific CD4 T Cell Reactivity in the General Population. Journal of Immunology, 2019, 203, 84-92.	0.8	36

#	Article	IF	CITATIONS
109	HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. Journal of Allergy and Clinical Immunology, 2019, 144, 183-192.	2.9	118
110	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Associated with Carbonic Anhydrase Inhibitors: Epidemiology, Genetics, and Insights into Mechanisms. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2854-2856.	3.8	0
111	Penicillin Allergy. New England Journal of Medicine, 2019, 381, 2338-2351.	27.0	159
112	Controversies in drug allergy: Testing for delayed reactions. Journal of Allergy and Clinical Immunology, 2019, 143, 66-73.	2.9	144
113	Sex-specific association between prenatal life stress exposure and infant pro-inflammatory cytokine levels during acute respiratory infection. Brain, Behavior, and Immunity, 2019, 76, 275-279.	4.1	3
114	The effect of delayed and early diagnosis in siblings, and importance of newborn screening for SCID. Annals of Allergy, Asthma and Immunology, 2019, 122, 211-213.	1.0	6
115	Prevention and Diagnosis of Severe T-Cell-Mediated Adverse Drug Reactions: Are We There Yet?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 228-230.	3.8	3
116	The safety of antibiotic skin testing in severe T-cell–mediated hypersensitivity of immunocompetent and immunocompromised hosts. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1341-1343.e1.	3.8	25
117	Antibiotic allergy. Lancet, The, 2019, 393, 183-198.	13.7	358
118	Delineation of the Individual Effects of Vitamin E Isoforms on Early Life Incident Wheezing. Journal of Pediatrics, 2019, 206, 156-163.e3.	1.8	10
119	Pathways to improved antibiotic allergy and antimicrobial stewardship practice: The validation of a beta-lactam antibiotic allergy assessment tool. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1063-1065.e5.	3.8	65
120	Incidence of Nephrotoxicity Among Pediatric Patients Receiving Vancomycin With Either Piperacillin–Tazobactam or Cefepime: A Cohort Study. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 221-227.	1.3	35
121	Dengue-specific CD8+ T cell subsets display specialized transcriptomic and TCR profiles. Journal of Clinical Investigation, 2019, 129, 1727-1741.	8.2	41
122	Update on Vitamin E and Its Potential Role in Preventing or Treating Bronchopulmonary Dysplasia. Neonatology, 2018, 113, 366-378.	2.0	33
123	Antibiotic Use After Removal of Penicillin Allergy Label. Pediatrics, 2018, 141, .	2.1	44
124	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>HLA</i> Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clinical Pharmacology and Therapeutics, 2018, 103, 574-581.	4.7	211
125	Effect of Maternal Smoking on Plasma and Urinary Measures of Vitamin E Isoforms in the First Month after Extreme Preterm Birth. Journal of Pediatrics, 2018, 197, 280-285.e3.	1.8	3
126	The Combined Utility of ExÂVivo IFN-γ Release Enzyme-Linked ImmunoSpot Assay and InÂVivo SkinÂTesting in Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1287-1296.e1.	3.8	47

#	Article	IF	CITATIONS
127	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 38-69.	3.8	134
128	Antibiotic Allergy in Pediatrics. Pediatrics, 2018, 141, .	2.1	83
129	Trends in health care utilization for asthma exacerbations among diverse populations with asthma in the United States. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 295-297.e5.	3.8	1
130	Seasonal patterns of Asthma medication fills among diverse populations of the United States. Journal of Asthma, 2018, 55, 764-770.	1.7	9
131	Research Directions in Genetic Predispositions to Stevens–Johnson Syndrome / Toxic Epidermal Necrolysis. Clinical Pharmacology and Therapeutics, 2018, 103, 390-394.	4.7	15
132	Minimal clinically important differences for measures of treatment efficacy in Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of the American Academy of Dermatology, 2018, 79, 1150-1152.	1.2	4
133	The impact of modifiable risk factor reduction on childhood asthma development. Clinical and Translational Medicine, 2018, 7, 15.	4.0	43
134	Precision HIV care: responding to old questions and meeting new challenges. Pharmacogenomics, 2018, 19, 1299-1302.	1.3	1
135	How antibiotic allergy labels may be harming our most vulnerable patients. Medical Journal of Australia, 2018, 208, 469-470.	1.7	15
136	A new model of wheezing severity in young children using the validated ISAAC wheezing module: A latent variable approach with validation in independent cohorts. PLoS ONE, 2018, 13, e0194739.	2.5	3
137	Infant Viral Respiratory Infection Nasal Immune-Response Patterns and Their Association with Subsequent Childhood Recurrent Wheeze. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1064-1073.	5.6	56
138	Reply. Journal of Allergy and Clinical Immunology, 2018, 141, 1957-1958.	2.9	3
139	A case of atypical, complete DiGeorge syndrome without 22q11Âmutation. Annals of Allergy, Asthma and Immunology, 2017, 118, 640-642.e2.	1.0	6
140	Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants. Science Translational Medicine, 2017, 9, .	12.4	105
141	Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 547-563.	3.8	106
142	Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences. Annals of Pharmacotherapy, 2017, 51, 1008-1022.	1.9	91
143	Impact of an Integrated Antibiotic Allergy Testing Program on Antimicrobial Stewardship: A Multicenter Evaluation. Clinical Infectious Diseases, 2017, 65, 166-174.	5.8	106
144	Pharmacogenomics of offâ€ŧarget adverse drug reactions. British Journal of Clinical Pharmacology, 2017, 83, 1896-1911.	2.4	48

#	Article	IF	CITATIONS
145	Anaphylaxis after zoster vaccine: Implicating alpha-gal allergy as a possible mechanism. Journal of Allergy and Clinical Immunology, 2017, 139, 1710-1713.e2.	2.9	61
146	Cytomegalovirus (CMV) Epitope–Specific CD4+ T Cells Are Inflated in HIV+ CMV+ Subjects. Journal of Immunology, 2017, 199, 3187-3201.	0.8	55
147	Severe Delayed Drug Reactions. Immunology and Allergy Clinics of North America, 2017, 37, 785-815.	1.9	27
148	The 3 Cs of Antibiotic Allergy—Classification, Cross-Reactivity, and Collaboration. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1532-1542.	3.8	60
149	Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles. Scientific Reports, 2017, 7, 8653.	3.3	41
150	Influence of Human Leukocyte Antigen (<scp>HLA</scp>) Alleles and Killer Cell Immunoglobulinâ€Like Receptors (<scp>KIR</scp>) Types on Heparinâ€Induced Thrombocytopenia (<scp>HIT</scp>). Pharmacotherapy, 2017, 37, 1164-1171.	2.6	14
151	Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema. Immunology and Allergy Clinics of North America, 2017, 37, 483-495.	1.9	35
152	Comparison of HLA allelic imputation programs. PLoS ONE, 2017, 12, e0172444.	2.5	58
153	Improving Antimicrobial Stewardship by Antibiotic Allergy Delabeling: Evaluation of Knowledge, Attitude, and Practices Throughout the Emerging Infections Network. Open Forum Infectious Diseases, 2016, 3, ofw153.	0.9	57
154	Classifying ADRs – does dose matter?. British Journal of Clinical Pharmacology, 2016, 81, 10-12.	2.4	27
155	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. New England Journal of Medicine, 2016, 375, 1749-1755.	27.0	1,668
156	Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses. Journal of Immunology, 2016, 196, 2205-2218.	0.8	55
157	Understanding the Association of Human Rhinovirus with Asthma. Vaccine Journal, 2016, 23, 6-10.	3.1	28
158	Medication Desensitization. Annals of Pharmacotherapy, 2016, 50, 203-208.	1.9	3
159	Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. Journal of Allergy and Clinical Immunology, 2015, 136, 262-271.e2.	2.9	51
160	Evolving models of the immunopathogenesis of TÂcell–mediated drug allergy: The role of host, pathogens, and drug response. Journal of Allergy and Clinical Immunology, 2015, 136, 219-234.	2.9	185
161	The evolving story of human leukocyte antigen and the immunogenetics of peanut allergy. Annals of Allergy, Asthma and Immunology, 2015, 115, 471-476.	1.0	12
162	Antiviral Drug Allergy. Immunology and Allergy Clinics of North America, 2014, 34, 645-662.	1.9	10

#	ARTICLE	IF	CITATIONS
163	Testing for drug hypersensitivity syndromes. Clinical Biochemist Reviews, 2013, 34, 15-38.	3.3	56
164	Role of selenium in HIV infection. Nutrition Reviews, 2010, 68, 671-681.	5.8	115
165	Personalizing antiretroviral therapy: is it a reality?. Personalized Medicine, 2009, 6, 393-408.	1.5	6
166	Pharmacogenetics and the potential for the individualization of antiretroviral therapy. Current Opinion in Infectious Diseases, 2008, 21, 16-24.	3.1	23